May 24, 2017
by Lysimachos Zografos
Comments Off on Parkure’s pipeline news: two drugs pre-clicanically validated.

Parkure’s pipeline news: two drugs pre-clicanically validated.

Two key pipeline compounds discovered by Parkure have been pre-clinically validated as part of a collaboration with Charles River Laboratories. Both drugs were found to rescue the symptoms of a virally induced rat model of Parkinson’s disease.

Beyond the progress for Parkure’s pipeline the results are indicative of the translational power of Parkure’s platform and it’s ability to discover drugs that act on validated Parkinson’s disease drug targets. The two drugs in question are repurposed but Parkure has already synthesised and tested novel chemical derivatives with very encouraging results.

April 21, 2017
by Lysimachos Zografos
Comments Off on New paper out

New paper out

We are committed to Parkinson’s research and our new paper on repurposing Astemizole and Ketoconazole is out (and free to access until May the 5th).

Abstract: Parkinson’s disease is a growing threat to an ever-ageing population. Despite progress in our understanding of the molecular and cellular mechanisms underlying the disease, all therapeutics currently available only act to improve symptoms and do not stop the disease process. It is therefore imperative that more effective drug discovery methods and approaches are developed, validated, and used for the discovery of disease-modifying treatments for Parkinson’s. Drug repurposing has been recognized as being equally as promising as de novo drug discovery in the field of neurodegeneration and Parkinson’s disease specifically. In this work, we utilize a transgenic Drosophila model of Parkinson’s disease, made by expressing human alpha-synuclein in the Drosophila brain, to validate two repurposed compounds: astemizole and ketoconazole. Both have been computationally predicted to have an ameliorative effect on Parkinson’s disease, but neither had been tested using an in vivo model of the disease. After treating the flies in parallel, results showed that both drugs rescue the motor phenotype that is developed by the Drosophila model with age, but only ketoconazole treatment reversed the increased dopaminergic neuron death also observed in these models, which is a hallmark of Parkinson’s disease. In addition to validating the predicted improvement in Parkinson’s disease symptoms for both drugs and revealing the potential neuroprotective activity of ketoconazole, these results highlight the value of Drosophila models of Parkinson’s disease as key tools in the context of in vivo drug discovery, drug repurposing, and prioritization of hits, especially when coupled with computational predictions.

April 11, 2017
by Lysimachos Zografos
Comments Off on Parkure at biotrinity 2017 London

Parkure at biotrinity 2017 London

Parkure will be one of the selected companies presenting at biotrinity 2017 in London. If you are attending the meeting you can catch our presentation  on Wednesday April 10th at 10:10 (early stage therapeutics track).

June 30, 2016
by Lysimachos Zografos
Comments Off on Parkure secures Innovation Voucher

Parkure secures Innovation Voucher

We are happy to announce that we have secured an Innovation Voucher in order to take the first steps into developing more novel tools and methods for in-vivo drug discovery.

logo

June 30, 2016
by Lysimachos Zografos
Comments Off on Parkure receives investment

Parkure receives investment

We are happy to officially announce that Parkure successfully raised an investment from Deepbride Capital LLP ( (DBC). DBC’s team includes experienced professionals in the field of Life Sciences and Technology. DBC will work closely with the management at Parkure to ensure we can make the best use of the resources, experience and connedeepbridge-logo

 

June 30, 2016
by Lysimachos Zografos
Comments Off on Life is people

Life is people

Our friend Simon shared this great video that his daughter Eliza produced. Working on drug discovery means that we have to deal with how nasty Parkinson’s is at the molecular and medical level on a daily basis. Watching this reminded us that the human side always prevails.

 

February 3, 2015
by Lysimachos Zografos
Comments Off on Parkure’s CEO awarded fellowship from Royal Society of Edinburgh

Parkure’s CEO awarded fellowship from Royal Society of Edinburgh

rse_enterprise_fellowships_logo_small

The Royal Society of Edinburgh (RSE) is Scotland’s national academy of science and letters. As part of their invaluable support to Scottish Life Sciences they offer Enterprise Fellowships in order to enable promising science and technology researchers to grow into successful entrepreneurs.

We are delighted to announce that Parkure’s CEO, Dr. Lysimachos Zografos was awarded the RSE  Enterprise Fellowship in order to pursuit the successful development of the company. The fellowship offers financial support as well as training, mentoring and access to networks of influential individuals.

February 3, 2015
by Lysimachos Zografos
Comments Off on Parkure at EIE15

Parkure at EIE15

Screen Shot 2015-02-02 at 18.33.45

We are delighted to announce that Parkure will be at this year’s instalment of Engage Invest Exploit (EIE15), Scotland’s premier technology investor showcase. EIE15 is organised by University of Edinburgh Informatics Ventures and offers the opportunity to a few selected companies to pitch to panels of investors.

After launching there last year, Parkure was invited again this time to show the progress made and interact with investors in order to raise funding for a full-scale screen of more than 40,000 compounds. Maximising the number of compounds we test will maximise the probability of finding drugs that can stop the progression of Parkinson’s, potentially leading to a cure.